Table 1: Acute vascular neurological manifestation in patients with SARV-CoV-2 infection.

Study

 

Patients

 

Age

 

Gender

 

UD

 

D-dimer

Type of stroke

 

Treatment

 

Outcome

Avula, et al. [6]

4

81*

75%, F

25%, M

Hypertension: 100%

Dyslipdemia: 75%

Diabetes: 25%

Elevated: 50%

IS

Aspirin

75% died

Saiegh, et al. [7]

2

46.5*

50%, F

50%, M

None: 50%

ns: 50%

ns

IS

ICH

External ventricular drain and

specific surgery

Survive

Beyrouti, et al. [8]

6

69.8*

33.3%, F

66.6%, M

Hypertension: 66.6%

Elevated: 100%

IS

Anticoagulation: 66.6%

Intravenous

thrombolysis:

16.6%

16.6% died

González-

Pinto, et al. [9]

1

36

F

ns

Elevated

IS

Supportive

Measures

Survive

Oxley, et al. [10]

5

40.4*

20%, F

80%, M

Hypertension: 20%

Dyslipdemia: 20%

Diabetes: 40%

Elevated: 60%

IS

Aspirin: 60%

Clot retrieval: 80%

Intravenous thrombolysis: 20%

Anticoagulation: 40%

Survive

Moshayei, et al. [11]

1

80

M

Heart failure, cardiovascular shock, and ischemic bilateral lower limbs

ns

IS

Supportive

measures

Survive

Hughes, et al. [12]

1

59

F

ns

ns

CVST

LMWH

Survive

Viguier, et al. [13]

1

73

M

ns

Elevated

IS

LMWH

Survive

Tunç, et al. [14]

4

65.3*

50% M

50% F

Diabetes: 25%

Hypertension:        75%

Elevated: 75%

IS

Antithrombotic therapy

Survive

Goldberg, et al. [15]

1

64

M

Hypertension, aplastic anemia, and splenectomy

Elevated

IS

ns

ns

*Median; F: female; M: male; y: years; UD: underlying disorders; IS: ischemic stroke; ICH: intracerebral hemorrhage; CVST: cerebral venous sinus thrombosis; ns: not specified; LMWH: low molecular weight heparin; D-dimer elevated levels: > 250 ng/ml.